<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102616">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02042560</url>
  </required_header>
  <id_info>
    <org_study_id>LORCERIE PARI 2010</org_study_id>
    <nct_id>NCT02042560</nct_id>
  </id_info>
  <brief_title>Physiopathology Study of Auto-immune Thrombopenia. Multicentre, Open, Controlled Study</brief_title>
  <official_title>Physiopathology Study of Auto-immune Thrombopenia. Multicentre, Open, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, open, case/control study aiming to investigate in a  quantitative and
      functional manner the different populations of immune cells in auto-immune thrombopenia
      with:

        1. Disturbed T lymphocyte response

             1. TH1 response predominant over TH2 response

             2. Implication of TH17 L

             3. Quantitative and/or functional deficit of regulatory T L

             4. Involvement anti-apoptotic mechanisms of TL

        2. Disturbed B lymphocyte response

             1. Hyperactivation of B lymphocytes and involvement of memory BL

             2. Secretion of autoantibodies

        3. Implication of ImC and disturbance of the pDC/mDC ratio

        4. Study of splenic immune cells (TL, BL, DC)

      The study will in no way modify the investigation procedures (diagnostic and therapeutic
      strategy), which will be carried out as usual.

      Blood samples related to the study will be taken in the context of a pathology investigation
      and will not require an additional puncture.

      Spleen samples will be obtained with the consent of the patient if therapeutic splenectomy
      is planned, which is usually proposed to patients with ITP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>T lymphocyte response</measure>
    <time_frame>Before and 4 to 8 weeks after  the initiation of therapeutic treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of thrombopoietin at the diagnosis and during the course of the disease, in patients who respond and don not respond to treatment</measure>
    <time_frame>Before and 4 to 8 weeks after  the initiation of therapeutic treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Idiopathic Thrombopenic Purpura (ITP)</condition>
  <arm_group>
    <arm_group_label>Patients with ITP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <arm_group_label>Patients with ITP</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spleen samples</intervention_name>
    <arm_group_label>Patients with ITP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persons who have provided written informed consent

          -  patients group: patients with ITP (defined as thrombopenia &lt; 30 000/mm3, once causes
             related to infection, medication, an auto-immune disease or malignant hemopathy have
             been eliminated)

          -  control group: persons who have provided written informed consent who do not meet the
             exclusion criteria

        Exclusion Criteria:

          -  persons without national health insurance cover

          -  persons less than 18 years old

          -  patients under guardianship or wards of court

          -  pregnant women

          -  control group: subjects presenting with an auto-immune disease, cancer, a progressive
             infection, or treated with corticoids or immunosuppressants cannot be included as
             controls.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylvain AUDIA</last_name>
    <phone>3.80.29.34.32</phone>
    <phone_ext>+33</phone_ext>
    <email>sylvain.audia@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine MAGGY-BERTRAND</last_name>
      <phone>3 81 66 82 33</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain AUDIA</last_name>
      <phone>3.80.29.34.32</phone>
      <phone_ext>+33</phone_ext>
      <email>sylvain.audia@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de METZ</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François MAURIER</last_name>
      <phone>3 87 39 47 72</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>January 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
